RAPID BREATH DETECTION OF LUNG CANCER

肺癌的快速呼吸检测

• 批准号: 8497529
• 负责人: PAUL RHODES
• 金额: $ 97.14万
• 依托单位: ISENSE MEDICAL CORPORATION
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-06-15 至 2014-06-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8497529
• 关键词: Adenocarcinoma Cell; Biological Assay; Breast; Breath Tests; Cancer Control; Cancer Detection; Cancer Patient; Cells; Clinic; Collection; Data Analyses; Detection; Development; Devices; Foundations; Gel; Generations; Lung; Malignant Neoplasms; Malignant neoplasm of lung; Medical; Metabolism; Modification; Monitor; Optics; Patients; Performance; Protocols documentation; Rest; Specificity; Staging; System; Technology; Testing; Treatment Efficacy; cancer diagnosis; cell type; chemotherapy; cost; next generation; sensor; tumor

The sensitivity of iSense Medical Corp (IMC) sensor system for the detection of a lung cancer signature from breath will be enhanced and demonstrated, a new breath collection device completed and a modification of the Cleveland Clinic Foundation (CCF) protocol for the ELDDA study of 8000 lung cancer patients and controls will be completed. The first generation of this non-invasive, inexpensice and rapid assay for the presence of lunf cancer has already been tested at CCF wwith specificity and selectivity of detection in the 80s. The next generation of this sensor array,comprising optical indicators embedded in a nanoporous sol-gel matrix is now>100x more sensitive to a range of lung cancer breath markers, enhancing sensitivty for a breast sensor technology already proven effective in lung cancer detection. The approved CCF protocol will be refined to assess the specific claim that following an indeterminate lung CT witht he IMC breath test reduces lung cancer diagnosis false positives over 200%. Further, as lung cancer breath signature arises from active tumor metabolism, the protocol will be adapted to test the hypothesis that the IMC breath rest represents a rapid and low-cost assessment for the efficacy of chemotherapy.

iSense Medical Corp（IMC）传感器系统检测呼吸中肺癌特征的灵敏度将得到增强和证明，新的呼吸采集设备将完成，克利夫兰临床基金会（CCF）方案的修改将完成，用于8000例肺癌患者和对照的ELDA研究。第一代这种非侵入性、廉价和快速的肺癌检测方法已经在CCF进行了测试，具有特异性和选择性检测。这种传感器阵列的下一代包括嵌入纳米多孔溶胶-凝胶基质中的光学指示器，现在对一系列肺癌呼吸标志物的敏感性提高了100倍以上，提高了乳腺传感器技术的灵敏度，该技术已被证明在肺癌检测中有效。将对已批准的CCF方案进行完善，以评估以下具体声明：在不确定的肺部CT和IMC呼吸试验后，肺癌诊断假阳性率降低200%以上。此外，由于肺癌呼吸特征是由活跃的肿瘤代谢引起的，因此该方案将适于测试以下假设：IMC呼吸休息代表了对化疗功效的快速且低成本的评估。